Prof Matthew Wright has over 28 years research experience with liver-related drug /chemical metabolism and toxicity. He was the first to demonstrate that stimulating liver myofibroblast apoptosis reversed fibrosis; developed a human single chain antibody to target these cells (licensed to Pharma) and demonstrated an anti-fibrogenic, and anti-inflammatory role for the PXR in the liver. Current research is focused on in vitro systems to model toxicity in the liver and the potential role of xenobiotics found in the environment as a trigger for the chronic liver disease. He has published in excess of 240 full research papers and scientific opinions; was an expert for the European Food Safety Authority ANS Panel (2011- 2018). He currently acts as an Associate Editor for the journal – Toxicology.